#### UNITED STATES PATENT AND TRADEMARK OFFICE

#### BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., and APOTEX, INC., Petitioners,

v.

REGENERON PHARMACEUTICALS, INC., Patent Owner.

Inter Partes Review No.: IPR2021-00881<sup>1</sup>

U.S. Patent No. 9,254,338 B2 Filed: July 12, 2013 Issued: February 9, 2016 Inventor: George D. Yancopoulos

Title: USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS

#### PETITIONER'S CORRECTED DEMONSTRATIVES FOR ORAL ARGUMENT

<sup>&</sup>lt;sup>1</sup> IPR2022-00258 and IPR2022-00298 have been joined with this proceeding.

# Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc. IPR2021-00880 & IPR2021-00881 Petitioner, Mylan Pharmaceuticals Inc. –Oral Argument–

August 10, 2022



# **'069 Patent: Anticipation Grounds 1-3**

#### The dosing regimen disclosures of Dixon, Heier-2009, and Regeneron April 2009 Press Release are <u>undisputed</u>.

- E.g., Dixon (Ground 2) discloses the VEGF Trap-Eye CLEAR-IT-2 trial: PRN dosing after 4 monthly loading doses (i.e., an initial dose and one or more secondary doses)
- Heier-2009 (Ground 1) discloses the same trial and regimen (Ex.1020)

(IPR2021-00880, Paper 1, 32-36, 45-50)

#### 2.6.2 Phase II

CLEAR-IT-2 trial [45] was a prospective, randomized, xpert multi-center, controlled dose- and interval-ranging Phase II trial in which 157 patients were randomized to five dose groups and treated with VEGF Trap-Eye in one eye. The mean age of the group was 78.2 years and all angiographic subtypes of CNV were represented at baseline. The mean ETDRS BCVA in letters at baseline was 56. Two groups received monthly doses of either 0.5 or 2.0 mg for 12 weeks (at weeks 0, 4, 8 and 12) and three groups received quarterly doses of either 0.5, 2.0 or 4.0 mg for 12 weeks (at weeks 0 and 12). Following this fixed dosing period, patients were treated with the same dose of VEGF Trap-Eye on a p.r.n. basis. Criteria for re-dosing included an increase in arma central retinal thickness of  $\geq 100 \ \mu m$  by OCT, a loss of  $\geq 5$ ETDRS letters in conjunction with recurrent fluid by OCT, persistent fluid as indicated by OCT, new onset classic neovascularization, new or persistent leak on FA or new macular subretinal hemorrhage.





# **'069 Patent: Anticipation Grounds 1-3**

- The dosing regimen disclosures of Dixon, Heier-2009, and Regeneron April 2009 Press Release are <u>undisputed</u>.
  - The Press Release discloses the VEGF Trap-Eye Phase 3 CRVO trials - PRN dosing after six monthly loading doses (i.e., an initial dose and one or more secondary doses) (IPR2021-00880, Paper 1, 45-53)

About the Phase 3 CRVO Program

•

In the Phase 3 CRVO program for VEGF Trap-Eye, Regeneron and Bayer HealthCare will conduct two identical multinational clinical studies: COPERNICUS (COntrolled Phase 3 Evaluation of Repeated iNtravitreal administration of VEGF Trap-Eye In Central retinal vein occlusion: Utility and Safety) will be led by Regeneron and GALILEO (General Assessment Limiting InfiLtration of Exudates in central retinal vein Occlusion with VEGF Trap-Eye) will be led by Bayer HealthCare. Enrollment will be initiated later in 2009.

Patients in both studies will receive 6 monthly intravitreal injections of either VEGF Trap-Eye at a dose of 2 milligrams (mg) or sham control injections. The primary endpoint of both studies is improvement in visual acuity versus baseline after 6 months of treatment. At the end of the initial 6 months, all patients will be dosed on a PRN (as needed) basis for another 6 months. All patients will be eligible for rescue laser treatment.

#### Ex.1028, Regeneron (30-April-2009)


Mylan v. Regeneron, IPR2021-00880

REGENERON



# **'069 Patent: Anticipation Grounds 1-3**

- Thus, Petitioner's asserted references cover each and every limitation of the claims
  - It is undisputed that the references disclose the dosing regimen steps and the molecule, VEGF Trap-Eye, also known as aflibercept
  - The sole dispute over Petitioner's anticipation grounds is over the sequence element (IPR2021-00880, Paper 68, 25-36)



Ex.1001, '069 patent, claim 1



#### Claim 1 of each patent sets forth the sequence of VEGF Trap-Eye/aflibercept

(IPR2021-00880, Paper 1, 45-50; IPR2021-00881, Paper 1, 39-44)

1. A method for treating an angiogenic eye disorder in a 1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF followed by one or more secondary doses of the VEGF : US 9,669,069 B2 US 9,254,338 B2 Feb. 9, 2016 antagonist, followed by one or more tertiary doses of the antagonist, followed by one or more tertiary doses of the 3/2006 Daly et al. 5/2006 Wegand et al. 5/2007 Shares VEGF antagonist; VEGF antagonist; 9 32010 9 122010 1 A2 22007 2 52018 wherein each secondary dose is administered 2 to 4 weeks wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose; and after the immediately preceding dose; and wherein each tertiary dose is administered on an aswherein each tertiary dose is administered at least 8 weeks needed/pro re nata (PRN) basis, based on visual and/or after the immediately preceding dose; wherein the VEGF antagonist is a VEGF receptor-based anatomical outcomes as assessed by a physician or chimeric molecule comprising (1) a VEGFR1 compoother qualified medical professional; nent comprising amino acids 27 to 129 of SEQ ID NO:2; wherein the VEGF antagonist is a receptor-based chime-(2) a VEGFR2 component comprising amino acids 130ric molecule comprising (1) a VEGFR1 component 231 of SEQ ID NO:2; and (3) a multimerization comcomprising amino acids 27 to 129 of SEQ ID NO:2; (2) ponent comprising amino acids 232-457of SEQ ID a VEGFR2 component comprising amino acids 130-NO:2. 231 of SEQ ID NO:2; and (3) a multimerization component comprising amino acids 232-457 of SEQ 2010-509369 3/2010 00/75319 12/2000 2000.065912 5/2000 ID NO:2. Mylan v. Regeneron, IPR2021-00880

Ex.1001, '338 patent, claim 1

Ex.1001, '069 patent, claim 1



#### No confusion among POSAs

Dixon discloses the use of
 VEGF Trap-Eye/aflibercept in
 AMD

Background: Age-related macular degeneration (AMD) affects > 14 million individuals worldwide. Although 90% of patients with AMD have the dry Drug Evaluation form, neovascular AMD accounts for the vast majority of patients who GF Trap-Eye for the treatment neovascular age-related develop legal blindness. Until recently, few treatment options existed for cular degeneration treatment of neovascular AMD. The advent of anti-VEGF therapy has significantly improved the safe and effective treatment of neovascular AMD. In addition to two anti-VEGF drugs currently in widespread use, ranibizumab and bevacizumab, a number of medications that interrupt angiogenesis are currently under investigation. One promising new drug is aflibercept (VEGF Trap-Eye), a fusion protein that blocks all isoforms of VEGF-A and placental growth factors-1 and -2. Objective: To review the current literature and clinical trial data regarding VEGF Trap-Eye for the treatment of neovascular AMD. Methods: Literature review. Results/conclusion: VEGF Trap-Eye is a novel anti-VEGF therapy, with Phase I and II trial data indicating safety, tolerability and efficacy for the treatment of neovascular AMD. Two Phase III clinical trials (VIEW-1 and VIEW-2) comparing VEGF Trap-Eye to ranibizumab are currently continuing and will provide vital insight into the clinical applicability of this drug.

(IPR2021-00880, Paper 1, 26-34, 54-58; Paper 56, 10-15) (IPR2021-00881, Paper 1, 23, 39-44; Paper 61, 23-27)

Ex.1006, Dixon, 1573



DEMONSTRATIVE EXHIBIT – NOT EVIDENCE

Mylan Exhibit 100

Mylan v. Regeneron, IPR2021-00880

#### No confusion among POSAs


• Adis c	liscloses the use of VEGF Trap-Eye/aflibercept in AMD	Adis R&D Profile
	Aflibercept is a fully human recombinant fusion protein composed of the second Ig domain of VEGFR1 and the third Ig domain of VEGFR2, fused to the Fc region of human IgG1. Aflibercept is in clinical development with Regeneror Pharmaceuticals and sanofi-aventis for the treatment of cancer, while Regeneror and Bayer are developing the agent for eye disorders. Aflibercept binds to a VEGF-A isoforms as well as placental growth factor (PIGF), thereby preventing these factors from stimulating angiogenesis. Blockade of VEGF can also prevented	Abstract Abs
Table I. Features and pro	blood vessel formation and vasuclar leakage associated with wet age-relate related ('s proprieta trap) certain	Regenerou and sanof-s-venis anended their allibercept collaboration agree- ment to include Janue. Under the terms of the amended agreement, reported in December 2005, the two companies will jointly develop and commercialize allibercept worldwide in all indications, except for intracended delivery to the cyc. sanof-s-venis paid SUS25 million to Regeneron for the inclusion of Japan and will pay milestene payments linked to Japanesc regulatory provals, plus royal- ties on Japanes aales, sanof-s-venis will lead Japanese development and will pay all development costs, however, Regeneron will repay SOW of these exploses out
CAS number WHO ATC code	862111-32-8 A10X (Other Drugs Used in Diabetes) S01X (Other Ophthalmologicals) L01 (Antineoplastic Agents)	of profas generated through the commercialization of allibercept. <sup>121</sup> annel sevenia sentimental is scontinuous to the allibercept avaganame in oncology in January 2005, while the exclusive rights to develop and commercial- ize the agent for eye disease through bound delivery systems evented to Regner- es. A \$1535, million clinical development millionity population to Regner- on A \$1535, million clinical development millionity and the approx- temper of the approxement of the approxement of the approxement A versitie (now another avents) and Regnerance netreed in a global (excluding Japan) agreement in September 2003 to jointly develop and commercialize affiberengt. Under the terms of the agreement, Avents in us to pay Regneran
EphMRA ATC code	A10X (Other Drugs Used in Diabetes) S1X (Other Ophthalmologicals) L1 (Antineoplastics)	SUS125 million and fund development costs. An additional early clinical nile- stone payment of SUS25 million was also outlined in the agreement. The two companies will alsae promotional rights equally, and profits globally. Aventis will also pay Regeneron up to SUS360 million at identified milestones related to the receipt of marketing approvals for up to eight indications in Europe and the
Originator Licensee companies	Regeneron Pharmaceuticals: USA Bayer HealthCare: world; sanofi-aventis: world	Mylan Exhibit 1007 Mylan v. Regeneron, IPR2021-00881 Page 1
Highest development phas	2021-00880, Paper 1, 26-34, 54-58; Paper 56, 10-15)	Ex.1007, Adis, 261, 264

(IPR2021-00881, Paper 1, 23, 39-44; Paper 61, 23-28)



#### No confusion among POSAs


 The aflibercept sequence was publicly available (IPR2021-00880, Paper 1, 26-29, 38-39; Paper 56, 7-9, 13-15) (IPR2021-00881, Paper 1, 24-25, 36-37; Paper 61, 22-28)





#### No confusion among POSAs

The VEGF Trap-Eye/aflibercept sequence was available to interested POSAs



Multiple VEGF Trap-Eye *and* aflibercept references refer back to Holash:

- Ex.2080, Heier ("VEGF Trap-Eye includes specific extracellular components of VEGF receptors 1 and 2 fused to the constant region (Fc) of IgG1," and citing to, and presenting data from, Holash)
- See also, e.g., Ex.1119 (referencing aflibercept and citing Holash); Ex.1120 (same); Ex.1123 (discussing VEGF Trap-Eye and citing Holash); Ex.1115, Gerritsen Reply Decl., ¶¶ 36-56



#### No confusion among POSAs


- Ex.1122: '069/'338 claimed sequence = prior art 2006 WHO Drug Info aflibercept sequence (Ex.1107) = prior art '758/'959
   Fig. 24 sequence of VEGFR1R2ΔC1(a) (SEQ ID NO: 16) (Ex.1010)
  - See also, e.g., Ex.1117 (aligning the '338 claimed sequence, the WHO aflibercept sequence, and the '173 patent, SEQ ID NO:2 sequence)

(IPR2021-00880, Paper 56, 13-15) (IPR2021-00881, Paper 61, 27-28)

	MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTS 60
SEQ ID 2 (338 & 069)	
Aflibercept (WHO 2006)	SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTS 34
758 SEQ ID 16	MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTS 60
959 SEQ ID 16	NVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTS 60
SEO ID 2 (338 & 069)	PNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLT 120
Aflibercept (WHO 2006)	PNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLT 94
758 SEO ID 16	PNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLT 120
	PNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLT 120
959 SEQ ID 16	PNITVIERRPPLDTEIPDGRRIIWDSRRGFIISNAITREIGELIGEATVNGHETRINTET 120
SEO ID 2 (338 & 069)	HROTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHOHKKLVNRD 180
Aflibercept (WHO 2006)	HRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRD 154
758 SEO ID 16	HROTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHOHKKLVNRD 180
959 SEO ID 16	HROTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWETPSSKHOHKKLVNRD 180
A2A 2EG ID 10	HRQTNIIIDVVLSPSHGIELSVGERLVLNCIARIELNVGIDENWEIPSSKHQHRRLVNRD 100
SEQ ID 2 (338 & 069)	LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC 240
Aflibercept (WHO 2006)	LKTOSGSENKKFLSTLTIDGVTRSDOGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC 214
758 SEO ID 16	LKTOSGSEMKKFLSTLTIDGVTRSDOGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC 240
959 SEQ ID 16	LKTOSGSENKKFLSTLTIDGVTRSDOGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC 240
222 2Ed ID ID	
SEQ ID 2 (338 & 069)	PAPELL6GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Aflibercept (WHO 2006)	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 274
758 SEQ ID 16	PAPELLGGPSVFLFPPKPKDTLMISRTPEVT&VVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
959 SEQ ID 16	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTQVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
SEQ ID 2 (338 & 069)	KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY 360
Aflibercept (WHO 2006)	KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY 334
758 SEQ ID 16	KPREEQYNSTYRVVSVLTVLHQDWLNGKEYK(KVSNKALPAPIEKTISKAKGQPREPQVY 360
959 SEQ ID 16	KPREEQYNSTYRVVSVLTVLHQDWLNGKEYK KVSNKALPAPIEKTISKAKG QPREPQVY 360
SEQ ID 2 (338 & 069)	TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK 420
Aflibercept (WHO 2006)	TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK 394
758 SEQ ID 16	TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK 420
959 SEQ ID 16	TLPPSRDELTKNQVSLTCLVKGFYPSDIAVENESNGQPENNYKTTPPVLDSDGSFFLYSK 420
SEO ID 2 (338 & 069)	LTVDKSRW00GNVFSCSVMHEALHNHYT0KSLSLSPGK 458
	LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG- 431
Aflibercept (WHO 2006)	
Aflibercept (WHO 2006) 758 SEQ ID 16 959 SEQ ID 16	LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 458 LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 458

Ex.1122, Amino Acid Alignment (*see also*, *e.g.*, Ex.1024 (Nucleic Acid Alignment))





it has to be read in the context of the entire document. as all other statements have to be.

Ex.1103, Klibanov Dep. Ex. 3, ¶¶ 76, 82-83

PROTECTIVE ORDER MATERIAL



#### PO's counter-arguments lack merit

- VEGF Trap-Eye not a genus
- Dixon and Adis refer to the agent in the singular, and disclose it in Phase 2 and Phase 3 clinical trials
- Regeneron's public disclosures make clear the ophtho and onco products contained the same active ingredient (aflibercept) (IPR2021-00880, Paper 56, 13-15; IPR2021-00881, Paper 61, 26-27)

1. Aflibercept (VEGF Trap) – Oncology

Aflibercept is a protein-based product candidate designed to bind all forms of Vascular Endothelial Growth Factor-A (called VEGF-A, also known as Vascular Permeability Factor or VPF), VEGF-B and the related Placental Growth Factor (called PIGF), and prevent their interaction with cell surface receptors. VEGF-A (and to a less validated degree, VEGF-B and PIGF) is required for the growth of new blood vessels (a process known as angiogenesis) that are needed for tumors to grow and is a potent regulator of vascular permeability and

2. VEGF Trap-Eye – Ophthalmologic Diseases

VEGF Trap-Eye is a specially purified and formulated form of VEGF Trap for use in intraocular applications) We and Bayer HealthCare are testing VEGF Trap-Eye in a Phase 3 program in patients with the neovascular form of age-related macular degeneration (wet AMD). We and Bayer HealthCare also are conducting a Phase 2 study of VEGF Trap-Eye in patients with diabetic macular edema (DME). Wet AMD and diabetic retinopathy (which includes DME) are two of the leading causes of adult blindness in the developed world. In both conditions, severe visual loss is caused by a combination of retinal edema and neovascular proliferation. We and Bayer HealthCare also initiated a Phase 3 program in Central Retinal Vein Occlusion (CRVO) in July 2009. In connection with the dosing of the first patient in a Phase 3 study in CRVO, we received a \$20.0 million milestone payment from Bayer HealthCare.

Ex.1021, 2009 10-Q, 18-19

10591-6707 (Zip Code)

v Section 13 or 15(d) of the Securit

Mylan Exhibit 1021 Mylan v. Regeneron, IPR2021-00880

10-Q 1 regeneron\_10q.htm QUARTERLY REPORT



#### PO's counter-arguments lack merit

Regeneron's public disclosures make clear the ophtho and onco products contained the same active ingredient (aflibercept) Angiogenesis An Integrative Approach From Science to Medicine Abstract: The inhibition of angiogenesis is proving to be Ex.1113, Rudge 2008 at 417-418: an effective strategy in treating diseases involving pathological angiogenesis such as cancer and ocular vascular diseases. "promising results...supported the Since its discovery in the 1980s, vascular endothelial cell introduction of VEGF Trap into the growth factor (VEGF) has been shown to play a vital role in both physiological and pathological angiogenesis, resulting in clinic for treatment of both wet the development of numerous approaches to block VEGF and VEGF signaling, ranging from small molecule tyrosine kinase AMD and diabetic macular inhibitors to protein-based and RNA-based therapeutic edema, using a version of VEGF candidates. VEGF Trap is one such protein-based agent that has been engineered to bind and sequester VEGF, as well as Trap specifically formulated for pringer placental growth factor (PIGF), with high affinity. VEGF Trap intra-ocular administration, has been shown to effectively inhibit pathological angiogenesis in numerous preclinical models of cancer and eye disease. Mylan Exhibit 1113 termed VEGF Trap-Eye." Mylan v. Regeneron, IPR2021-00880 and is now being evaluated in clinical trials in several types of (IPR2021-00880, Paper 56, 13-15) cancer, as well as the 'wet' or neovascular form of age-related Ex.1113, Rudge 2008, 415 macular degeneration (AMD). This chapter will summarize (IPR2021-00881, Paper 61, 26 n.13, 26-28) the basic biology of VEGF and the progress of the VEGF Trap from the bench to the clinic.





٠

#### PO Should Be Held To Its Prosecution Representations

 "In accordance with a dosage regimen as claimed in independent claim 1" (IPR2021-00880, Paper 56, 18-20)

The Heier et al. paper shows results of a treatment protocol of the type claimed or	PRELIMINARY Attorney Docket No. REGN-008CIPCON			
patients. The studies summarized in the Heier et al. paper correspond to the clinical trials	al Soo Patrit Application Group Art Unit To Be Assigned			
Example 4 of the present application which involve the use of the VEGF receptor-based of	chimeric biles biles biles and set S			
molecule known as aflibercept or "VEGF Trap." <sup>1</sup> The results clearly show that by admin	istering the Pror to the examination of the above-referenced application on the metrix, please enter the adments below.			
VEGF antagonist in accordance with a dosage regimen as claimed in independent claim 1	, it is possible			
to treat angiogenic eye disorders such as AMD while administering doses on a less freque	ent basis than			
previously thought possible. This provides enormous benefits to patients, reduces health	care cost,			
Within the "Discussion" section of the Heier et al. paper, it is noted that the treatment group				
treated every two months achieved a visual acuity score within 0.3 letters of the group treated on a				
monthly basis. See also the results summarized in Table 1, page 15, of the present application. Thus, it				
is indicated that the treatment group which received the drug far less frequently than the monthly dosing				
arm achieved remarkably similar improvements without requiring the monthly monitoring and visits to $\frac{1}{2}$				
the health care provider. Ex.1017, '069 PH, 136-13				



#### Dixon Anticipates

 Dixon discloses VIEW's second year of PRN dosing (IPR2021-00880, Paper 56, 20-21)

#### 2.6.3 Phase III

A two part Phase III trial of VEGF Trap-Eye was initiated in August of 2007. The first part, VIEW 1 (VEGF Trap: Investigation of Efficacy and safety in Wet age-related macular degeneration) [46] will enroll ~ 1200 patients with neovascular AMD in the US and Canada. This non-inferiority study will evaluate the safety and efficacy of intravitreal VEGF Trap-Eye at doses of 0.5 and 2.0 mg administered at 4-week dosing intervals and 2.0 mg at an 8 week dosing interval (following three monthly doses), compared with 0.5 mg of 1a ranibizumab administered every 4 weeks. After the first year of the study, patients will enter a second year of p.r.n. dosing evaluation. The VIEW 2 [47] study has a similar study design and is currently enrolling patients in Europe, Asia Pacific, Japan and Latin America. In both trials, the primary outcome will be the proportion of patients who maintain vision at week 52 (defined as a loss of < 15 ETDRS letters).



Ex.1006, Dixon, 1576



#### Dixon Renders Obvious

 3 monthly loading doses + PRN maintenance (IPR2021-00880, Paper 56, 21-24)

#### 2.6.3 Phase III

A two part Phase III trial of VEGF Trap-Eye was initiated in August of 2007. The first part, VIEW 1 (VEGF Trap: Investigation of Efficacy and safety in Wet age-related macular degeneration) [46] will enroll ~ 1200 patients with neovascular AMD in the US and Canada. This non-inferiority study will evaluate the safety and efficacy of intravitreal VEGF Trap-Eye at doses of 0.5 and 2.0 mg administered at 4-week dosing intervals and 2.0 mg at an 8 week dosing interval (following three monthly doses), compared with 0.5 mg of 1a ranibizumab administered every 4 weeks. After the first year of the study, patients will enter a second year of p.r.n. dosing evaluation. The VIEW 2 [47] study has a similar study design and is currently enrolling patients in Europe, Asia Pacific, Japan and Latin America. In both trials, the primary outcome will be the proportion of patients who maintain vision at week 52 (defined as a loss of < 15 ETDRS letters).



Ex.1006, Dixon, 1576



#### **Dixon Renders Obvious**

Dixon sets forth motivation . . . (IPR2021-00880, Paper 56, 21-24, 25-31)

> As previously mentioned, the MARINA [26] and the ANCHOR [27,28] trials examined the efficacy of ranibizumab when administered monthly. The time and financial burden of monthly injections has led to the initiation of studies to examine the efficacy of alternative dosing schedules. In the

Current treatment regimens with either ranibizumab or bevacizumab now afford stabilization of vision in > 90% of patients, with significant vision gain in one-third of all patients treated. There have been no significant, proven adverse systemic effects with the intraocular use of either drug. However, limitations of current therapy include the need for frequent intraocular injections, as often as monthly, without a defined stopping point. Each injection subjects patients to risks of cataract, intraocular inflammation, retinal detachment and endophthalmitis. A significant time and financial burden falls on patients during their treatment course.



Drug Evaluation

VEGF Trap-Eye for the treatment

Ex.1006, Dixon, 1574, 1577



#### Dixon Renders Obvious

 Dixon provides motivation and a reasonable expectation of success . . .

(IPR2021-00880, Paper 56, 21-24)

#### 2.6.2 Phase II

CLEAR-IT-2 trial [45] was a prospective, randomized, multi-center, controlled dose- and interval-ranging Phase II trial in which 157 patients were randomized to five dose groups and treated with VEGF Trap-Eye in one eye. The mean age of the group was 78.2 years and all angiographic subtypes of CNV were represented at baseline. The mean ETDRS BCVA in letters at baseline was 56. Two groups received monthly doses of either 0.5 or 2.0 mg for 12 weeks (at weeks 0, 4, 8 and 12) and three groups received quarterly doses of either 0.5, 2.0 or 4.0 mg for 12 weeks (at weeks 0 and 12). Following this fixed dosing period, patients were treated with the same dose of VEGF Trap-Eye on a p.r.n. basis. Criteria for re-dosing included an increase in central retinal thickness of  $\geq 100 \ \mu m$  by OCT, a loss of  $\geq 5$ ETDRS letters in conjunction with recurrent fluid by OCT, persistent fluid as indicated by OCT, new onset classic neovascularization, new or persistent leak on FA or new macular subretinal hemorrhage.

Patients initially treated with 2.0 or 0.5 mg of VEGF Trap-Eye monthly achieved mean improvements of 9.0 (p < 0.0001) and 5.4 (p < 0.085) ETDRS letters with 29 and 19% gaining, respectively,  $\geq$  15 ETDRS letters at 52 weeks. During the p.r.n. dosing period, patients initially dosed on a 2.0 mg monthly schedule received an average of 1.6 more injections and those initially dosed on a 0.5 mg monthly schedule received an average of 2.5 injections. The median time to first reinjection in all groups was 110 days and 19% of patients required no more injections at week 52. Patients in these two monthly dosing groups also displayed mean decreases in

# <page-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header>

#### Ex.1006, Dixon, 1576

Rage 1



#### PO counter-arguments lack merit

Abundant evidence of motivation to minimize number of injections

(IPR2021-00880, Paper 1, 58-59; Ex.1002, Dr. Albini Decl., ¶¶ 59-60, 168-171)

- Demonstrated ability to minimize injections using a PRN regimen
  - PRN Phase 2 = <u>5.6</u> injections in first year
  - Every-8-week dosing = <u>8</u> injections in first year
  - Monthly = <u>12</u> injections in first year

(IPR2021-00880, Paper 1, 60) (IPR2021-00880, Paper 56, 21-24, 25-31) 59. Intravitreal treatment involves administering an injection directly into the vitreous of the eye. Because of this, patients can experience significant pain and discomfort. Soreness in the injected eye is a frequent side effect. In addition, potential complications that can occur include subconjunctival hemorrhage, infection, and inflammation. While the risk of infection is small, the consequences can be devastating. Lastly, the cost and inconvenience of monthly visits and injections can be a major drawback for patients, many of whom are elderly, cannot drive due to their deteriorating vision, and must rely on family, friends, or public transportation to get to their appointments—which can sometimes take 2-5 hours because of the assessments (optical coherence tomography (OCT) scan and visual acuity (VA)) that must be done, followed by the actual treatment, if necessary.

#### Ex.1002, Dr. Albini Decl., ¶ 59

171. For example, Dixon disclosed that PRN dosing in the Phase 2 trial (CLEAR-IT-2) had led to mean increases in visual acuity and mean decreases in retinal thickness. The one-year results discussed in Dixon show that in the randomized 157 patient trial, patients that were treated with 2.0 mg monthly doses at weeks 0, 4, 8, and 12, followed by PRN dosing, exhibited mean improvements of 9.0 letters in visual acuity and a mean decrease in retinal thickness of 143 μm. Further, the study showed that the median time to first reinjection after the loading dose phase was 110 days, and that patients that received monthly loading doses of 2.0 mg required on average only 1.6 more injections between weeks 12 and 52.

#### Ex.1002, Dr. Albini Decl., ¶ 171



•

#### PO counter-arguments lack merit

- PRN dosing not burdensome
- Nothing in claims or specification about PRN requiring monthly visits
- PO disregards PRN/as-needed regimens that did not involve monthly visits (Ex.2103, 2-3; Ex.1049, 24)

(IPR2021-00880, Paper 56, 21-24, 31-36)

**Dr. Brown:** For patients with good initial visual acuity or in whom we are dealing with the primary eye, I treat and extend from the start. I give 3 monthly injections and see them in 8 weeks. If fluid is absent at that visit, I give another injection and see them in 10 weeks.

Ex.2103, Retinal Physician, 2

15 But our clinical practice, as was stated in the


16 2007 paper, was to give three monthly doses, and17 then assess how the patient is doing.

Ex.1110, Brown Tr., 149:15-17



#### PO counter-arguments lack merit

- '069 claims directed to the prevailing trend for treating AMD (Ex.2259, 17; Ex.2103, 2-3)
- Dr. Albini testified that minimizing injections was the primary focus (IPR2021-00880, Paper 56, 18-35)



Ex.1114, Dr. Albini Reply Decl., ¶ 28



#### PO counter-arguments lack merit

• Regeneron implemented PRN dosing in at least six clinical trials prior to 2010 (IPR2021-00880, Paper 56, 20-24)

Trial	Disorder	Evidence
CLEAR-IT-2 (Phase 2)	AMD	Ex.1020; Ex.1006; Ex.1055
VIEW1 & VIEW2 (Phase 3)	AMD	Ex.1006
DME (Phase 2)	DME	Ex.1068
COPERNICUS (Phase 3)	CRVO	Ex.1028
GALILEO (Phase 3)	CRVO	Ex.1028



#### Heier-2009 (PRN dosing) + Dixon/Mitchell (3 monthly loading doses) render obvious CLEAR-IT 2 was a double-masked multicenter trial

- Heier-2009 = successful PRN dosing
- Heier-2009 showed significant ٠ increases in visual acuity with only 7.5 doses over 18 months (4 loading doses + 3.5 PRN doses over next 15

months)

(IPR2021-00880, Paper 56, 25-31)

age, best-corrected visual acuity (BCVA) at baseline, At 1 year, for all treated groups combined (n=157), there was a significant improvement in BCVA from baseline (mean improvement 5.3 letters; P<.0001). Patients who received three monthly doses of 2.0 mg followed by as-needed dosing achieved mean improvements in BCVA of 9.0 letters from baseline (P<.0001 vs


In the original study, the mean gain in BCVA from baseline for the 117 patients who entered the extension stage was 7.3 letters (P<.0001 vs baseline) at the 3-month primary endpoint of the original study, 8.4 letters (P<.0001 vs baseline) at 1 year, and 7.1 letters (P<.0001 vs baseline) at month 6 of the extension study. Over the 15-month course of the PRN dosing phase, from month 3 of the original study to month 6 of the extension phase, patients received a mean 3.5 injections of VEGF Trap-Eye.


reived three monthly doses of eded dosing achieved mean ters from baseline (P<.085 vs year. Patients who received iniowed by as-needed dosing also but they were generally not as with initial monthly dosing.

in which patients with neovascular AMD were randomly assigned to receive monthly intravitreal injec-

tions of VEGF Trap-Eye 0.5 mg or 2.0 mg or quarterly

injections of 0.5, 2.0 or 4.0 mg for an initial 3-month





Ex.1020, Heier-2009, 45



#### Heier-2009 (PRN dosing) + Dixon/Mitchell (3 monthly loading doses) render obvious

 Dixon = 3 monthly loading doses of aflibercept in AMD

(IPR2021-00880, Paper 56, 25-31)

#### 2.6.3 Phase III

A two part Phase III trial of VEGF Trap-Eye was initiated in August of 2007. The first part, VIEW 1 (VEGF Trap: Investigation of Efficacy and safety in Wet age-related macular degeneration) [46] will enroll ~ 1200 patients with neovascular AMD in the US and Canada. This non-inferiority study will evaluate the safety and efficacy of intravitreal VEGF Trap-Eye at doses of 0.5 and 2.0 mg administered at 4-week dosing intervals and 2.0 mg at an 8 week dosing interval (following three monthly doses), compared with 0.5 mg of ranibizumab administered every 4 weeks. After the first year of the study, patients will enter a second year of p.t.n. dosing evaluation. The VIEW 2 [47] study has a similar study design and is currently enrolling patients in Europe, Asia Pacific, Japan and Latin America. In both trials, the primary outcome will be the proportion of patients who maintain vision at week 52 (defined as a loss of < 15 ETDRS letters).



#### Ex.1006, Dixon, 1576




#### Heier-2009 (PRN dosing) + **Dixon/Mitchell (3 monthly** loading doses) render obvious

Mitchell = 3 monthly loading doses of anti-VEGF therapy in AMD

(IPR2021-00880, Paper 56, 25-31)

The small, open-label, prospective, single-centre, non-randomised, investigator-sponsored PrONTO study assessed three consecutive monthly injections followed by OCT-guided variable dosing (at ≥1 month intervals).<sup>32</sup> Retreatment criteria were: fiveletter loss in the presence of fluid at the macula detected by optical coherence tomography (OCT); ≥100 µm increase in central retinal thickness (CRT); new-onset classic choroidal neovascularisation (CNV); new macular haemorrhage; or persistent macular fluid detected by OCT. While similar VA outcomes to the MARINA and ANCHOR trials were demonstrated but with fewer intravitreal injections (figs 1E, 4; tables 2, 3), substantial trial design differences limit comparisons. Although small and open label, this study suggests that flexible OCT-guided retreatment could sustain visual gain with fewer injections.



Ex.1030, Mitchell, 5, 6



DEMONSTRATIVE EXHIBIT – NOT EVIDENCE

O -5

-10

#### Heier-2009 (PRN dosing) + Dixon/Mitchell (3 monthly loading doses) render obvious


Motivation: Reducing injection frequency

(IPR2021-00880, Paper 56, 25-36)

 Patients initially treated with 2.0 or 0.5 mg of VEGF Thread and 5.4 (p < 0.085) ETDRS letters at 52 weeks. During the p.r.n. dosing period, patients initially dosed on a 2.0 mg monthly schedule received an average of 1.6 more injections and those initially dosed on a 0.5 mg monthly schedule received an average of 2.5 injections. The median time to the function of the state of the state

Expert

Ex.1006, Dixon, 1576





#### DEMONSTRATIVE EXHIBIT – NOT EVIDENCE

Drug Evaluation

VEGF Trap-Eye for the treatment

#### Heier-2009 (PRN dosing) + Dixon/Mitchell (3 monthly loading doses) render obvious

 Reasonable expectation of success: improvements in visual acuity and retinal thickness in CLEAR-IT-2

(IPR2021-00880, Paper 1, 60-69, Paper 56, 27, 31-36); Ex.1002, Dr. Albini Decl., ¶¶ 95-

Patients initially treated with 2.0 or 0.5 mg of VEGF Trap-Eye monthly achieved mean improvements of 9.0 (p < 0.0001) and 5.4 (p < 0.085) ETDRS letters with 29 and 19% gaining, respectively,  $\geq 15$  ETDRS letters at 52 weeks. During the p.r.n. dosing period, patients initially dosed on a 2.0 mg monthly schedule received an average of 1.6 more injections and those initially dosed on a 0.5 mg monthly schedule received an average of 2.5 injections. The median time to first reinjection in all groups was 110 days and 19% of patients required no more injections at week 52. Patients in these two monthly dosing groups also displayed mean decreases in

retinal thickness versus baseline of 143  $\mu$ m (p < 0.0001) in the 2.0 mg group and 125  $\mu$ m (p < 0.0001) in the 0.5 mg group at 52 weeks as measured by OCT [45].

Patients in the three quarterly dosing groups also showed mean improvements in BCVA and retinal thickness; however, they were generally not as profound as the monthly injection group [45].

# <section-header><section-header><section-header><section-header><text><text><text>

Drug Evaluation

Agendant massis deposition (MMV) afters  $\pm$  15% million infolds the fits (MMV) afters and the MMV after and the MMV aft

Ex.1006, Dixon, 1576

there was a significant improvement in BCVA from baseline (mean improvement 5.3 letters; P<.0001). Patients who received three monthly doses of 2.0 mg followed by as-needed dosing achieved mean improvements in BCVA of 9.0 letters from baseline (P<.0001 vs) baseline). Those who received three monthly doses of 0.5 mg followed by as-needed dosing achieved mean improvements of 5.4 letters from baseline (P<.085 vs baseline) at the end of 1 year. Patients who received initial quarterly dosing followed by as-needed dosing also achieved gains in BCVA, but they were generally not as robust as those achieved with initial monthly dosing. Patients receiving initial monthly doses of VEGF Trap-Eye achieved mean decreases in retinal thickness vs

At 1 year, for all treated groups combined (n=157),

COVER STORY

baseline at 1 year. In addition, treatment with VEGF Trap-Eye was associated with a reduction in the size of the total active choroidal neovascular membrane (CNV).



presented at the Association for Research in Vision phthalmology (ARVO) earlier this year<sup>2</sup> This artinews results of the initial CLEAR-IT 2 as well as som the extension stage.

Mylan v. Regeneron, IPR2021-00880 Page 1

#### Ex.1020, Heier-2009, 45



96, n.15

#### DEMONSTRATIVE EXHIBIT – NOT EVIDENCE

Mylan Exhibit 1020

#### PO counter-arguments lack merit

- Motivation to reduce injections not limited to "chronic dosing"
- Mitchell expressly suggested fewer loading doses

(IPR2021-00880, Paper 56, 25-28, 34-35)

**Results:** Ranibizumab is indicated for choroidal neovascular lesions with active disease, the clinical parameters of which are outlined. Treatment initiation with three consecutive monthly injections, followed by continued monthly injections, has provided the best visual-acuity outcomes in pivotal clinical trials. If continued monthly injections are not feasible after initiation, a flexible strategy appears viable, with monthly monitoring of lesion activity recommended. Initiation regimens of fewer than three injections have not been assessed. Continuous careful monitoring with flexible retreatment may help avoid vision loss recurring. Standardised biomarkers need

MARINA, ANCHOR<sup>12 13 24</sup> and the EXCITE ranibizumab active control arm<sup>31</sup> were the only Phase III studies with monthly injections throughout the whole treatment period. Most VA improvement was seen during the initial 3-month phase with subsequent injections appearing to maintain the achieved benefit (fig 2). Prospective clinical trials would be valuable for investigating fewer injections in the initiation phase.

Ex.1030, Mitchell, 2, 4

Ranibizumab (Lucentis) in neovascular age-related

macular degeneration: evidence from clinical trials

P Mitchell <sup>1</sup> LF Kombelnik <sup>2</sup> P Lanzetta <sup>3</sup> F G

RMMS

#### PO arguments lack merit

- CLEAR-IT-2 data would not discourage 3 monthly loading doses
- Dixon disclosed the implementation of 3 loading doses for Phase 3 VIEW trials, i.e., dropping from 4 loading doses (Phase 2) to three loading doses (Phase 3)

(IPR2021-00880, Paper 56, 20-26, 34-36)

#### 2.6.3 Phase III

A two part Phase III trial of VEGF Trap-Eye was initiated in August of 2007. The first part, VIEW 1 (VEGF Trap: Investigation of Efficacy and safety in Wet age-related macular degeneration) [46] will enroll ~ 1200 patients with neovascular AMD in the US and Canada. This non-inferiority study will evaluate the safety and efficacy of intravitreal VEGF Trap-Eye at doses of 0.5 and 2.0 mg administered at 4-week dosing intervals and 2.0 mg at an 8 week dosing interval (following three monthly doses), compared with 0.5 mg of ranibizumab administered every 4 weeks. After the first year of the study, patients will enter a second year of p.r.n. dosing evaluation. The VIEW 2 [47] study has a similar study design and is currently enrolling patients in Europe, Asia Pacific, Japan and Latin America. In both trials, the primary outcome will be the proportion of patients who maintain vision at week 52 (defined as a loss of < 15 ETDRS letters).

Expert

#### Drug Evaluation

#### VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration

mes A Dixon, Scett CN Oliver<sup>1</sup>, Jeffrey L Olson & Naresh Mandava inessig of Garrada Danas. Body Menatic Linu Lp Instant. Department of Opinidendags 20 March Lenge ND Res (2016) Mol Res (2016) August 2016 (2016) 2018

#### Endpanser: Age entitient moulds dependentient (MME) effects - 1 minori biodivalus activation, MMA; they dis plant main with ABD ber the disfactors, insteadure AMD, inclusions to the watt majority of plantsmither topped activation of the sectors of the sectors of the sectors of the plantsmither and the sectors of the sectors of the sectors of the plantsmither and the sectors of the sectors of the sectors of the plantsmither and the sectors of the sectors of the sectors of the plantsmither and the sectors of the sectors of the sectors of the plantsmither and the sectors of the sectors of the sectors of the plantsmither and the sectors of the sectors of the sectors of the plantsmither and the sectors of the sectors and the sectors of the sectors and sectors of the sectors are reserved continuing and all provide that insigns in the discillation (STE). They for the sectors are all the sectors of the s

Senseting and senseting (MM) gifters + 15% silline includes in the high senseting (MM) gifters + 15% silline includes in the high senseting (MM) sensetin

Ex.1006, Dixon, 1576


Page 1



#### PO arguments lack merit

- CLEAR-IT-2 data would not discourage 3 monthly loading doses
  - Dr. Brown argues that the typical practice was to treat with loading doses until the retina was dry (Ex.2050, ¶¶ 141-142)
  - No significant change in retinal thickness after the first couple loading doses (Ex.1114, Albini Reply, ¶ 33) (IPR2021-00880, Paper 56, 31-36)

#### Mean Change in Central Retinal/Lesion Thickness



Ex.1055, Retina Society, 18 (emphasis added)




٠

•

# IPR2021-00881 (U.S. Patent No. 9,254,338)

#### • Challenged Claims: 1, 3-11, 13-14, 16-24, and 26

- Claims broadly directed to administering VEGF Trap-Eye under a specific temporal sequences of doses (i.e., "Q8" dosing).
  - Clear, plain and ordinary meaning
  - Supported by and consistent with intrinsic record (including express definitions)



# Person of Ordinary Skill in the Art ("POSA")

		Pa	atent Owner
•	<b>Board:</b> "Petitioner's definition of [a POSA] is reasonable and consistent with the [challenged] patent and prior art of record." (Paper 21, 15)	•	<b>POR and Dr. Do:</b> Disagree with Petitioner's definition; POSA <i>must</i> be a licensed physician (ophthalmologist). (Ex.2051, Do Decl., ¶28)
•	<b>Petitioner Reply:</b> PO experts applied <i>different,</i> <i>incompatible</i> POSA perspectives; Inventor and Dr. Klibanov not a POSA under PO's definition. (Paper 61, 4-6)	•	<b>Sur-reply:</b> "[T]he Board need not make specific findings as to the level of the POSA." (Paper 73, 2)

• "The level of skill in the art is a factual determination that provides a primary guarantee of objectivity in an obviousness analysis." (Paper 21, 15 (*citing Al-Site Corp. v. VSI Int'l, Inc.*, 174 F.3d 1308, 1323 (Fed. Cir. 1999))).

RMMS

# **'338 Patent: Claim Construction**

"method for treating an angiogenic eye disorder in a patient"

	Patent Owner
• <b>Board:</b> "[T]he preambles of the independent claims do not require the recited method steps to provide an effective treatment." (Paper 21, 21)	<ul> <li>"where a 'method for treating' is limiting, the claims <i>require</i> efficacy" (Paper 73, 2)</li> </ul>
<ul> <li>Petitioner: If limiting: "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22)</li> </ul>	
<ul> <li>Petitioner: Claims encompass all levels of efficacy, not just a "high" one (Paper 61, 9)</li> </ul>	<ul> <li>"treating" requires a "high level of efficacy" (Paper 73, 3)</li> </ul>
<ul> <li>Clear intrinsic record</li> <li>Preserves the intended scope and patent's notice function</li> <li>Applies to all embodiments</li> </ul>	<ul> <li>Extrinsic evidence</li> <li>Contradicts intrinsic record</li> <li>Eliminates notice function</li> <li>Excludes embodiments</li> </ul>



# **'338 Patent: Claim Construction**

#### "method for treating an angiogenic eye disorder in a patient"

#### Challenged Claim 1 ('338 Patent):

#### **Intrinsic Evidence – The Claims**

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

Petitioner: If limiting: "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22; Paper 61, 7) Plain language of the Claims do not set forth any efficacy requirement. (Paper 1, 20-22; *see also* Paper 61, 7-8 (quoting *Kaneka*) ("Claim construction begins with the language of the claims."))

Ex.1001, '338 patent, 23:2-24:53 (claims)

**Board:** "Patent Owner does not direct us to any other portion of the claims ... that supports finding that the claimed method for treating ... requires such treatment method to have any particular level of effectiveness." (Paper 21, 20)

Ex.1001, '338 patent, claim 1



# **'338 Patent: Claim Construction**

#### "method for treating an angiogenic eye disorder in a patient"

#### Challenged Claim 1 ('338 Patent):

#### Intrinsic Evidence – The Specification

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;


Petitioner: If limiting: "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22; Paper 61, 7) Intrinsic record describes the method as *sequentially administered doses* (no mention of efficacy)

immediately preceding dose. An example of a dosing regimen of the present invention is shown in FIG. 1. One advantage of

FIG. 1 shows an exemplary dosing regimen of the present invention. In this regimen, a single "initial dose" of VEGF antagonist ("VEGFT") is administered at the beginning of the treatment regimen (i.e. at "week 0"), two "secondary doses" are administered at weeks 4 and 8, respectively, and at least six "tertiary doses" are administered once every 8 weeks thereafter, i.e., at weeks 16, 24, 32, 40, 48, 56, etc.).

#### Dosing Regimens

The present invention provides methods for treating angiogenic eye disorders. The methods of the invention comprise sequentially administering to a patient multiple doses of a VEGF antagonist. As used herein, "sequentially administer-



Ex.1001, '338 patent, claim 1

Ex.1001, '338 patent, 2:14-15, 54-55, Fig.1, 3:19-26 (Paper 61, 2, 9-10)



## "method for treating an angiogenic eye disorder in a patient"

### Challenged Claim 1 ('338 Patent):

#### Intrinsic Evidence – The Specification

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

Petitioner: If limiting: "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22; Paper 61, 7)

Ex.1001, '338 patent, claim 1

Intrinsic evidence expressly encompasses *all levels of efficacy*, not just a "high" one

complications. Release of vascular endothelial growth factor (VEGF) contributes to increased vascular permeability in the eye and inappropriate new vessel growth. Thus, inhibiting the angiogenic-promoting properties of VEGF appears to be an effective strategy for treating angiogenic eye disorders.

Treatment Population and Efficacy

The methods of the present invention are useful for treating angiogenic eye disorders in patients that have been diagnosed with or are at risk of being afflicted with an angiogenic eye disorder. Generally, the methods of the present invention demonstrate efficacy within 104 weeks of the initiation of the treatment regimen (with the initial dose administered at

Ex.1001, '338 patent, 1:44-48, 7:15-21

(Paper 61, 7-12)



## "method for treating an angiogenic eye disorder in a patient"

#### **Challenged Claim 1 ('338 Patent):**

### Intrinsic Evidence – The Specification

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

Petitioner: If limiting: "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22; Paper 61, 7) Intrinsic evidence expressly encompasses *all levels of efficacy*, not just a "high" one

one or more tertiary doses of the VEGF antagonists. The present inventors have surprisingly discovered that beneficial therapeutic effects can be achieved in patients suffering from angiogenic eye disorders by administering a VEGF antagonist to a patient at a frequency of once every 8 or more weeks, especially when such doses are preceded by about three doses administered to the patient at a frequency of about 2 to 4 weeks. Thus, according to the methods of the present inven-

Ex.1001, '338 patent, 2:3-10

(Paper 61, 7-12)

**Board:** "Without more, we do not find the disclosure that such effects 'can be achieved' demonstrates adequately that the claims *require* any particular level of efficacy." (Paper 21, 21)

Ex.1001, '338 patent, claim 1



## "method for treating an angiogenic eye disorder in a patient"

#### **Challenged Claim 1 ('338 Patent):**

### Intrinsic Evidence – The Specification

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

Petitioner: If limiting, "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22; Paper 61, 7) Intrinsic evidence expressly defines "therapeutically effective amount" as doses resulting in *all levels of efficacy* 

The amount of VEGF antagonist administered to the patient in each dose is, in most cases, a therapeutically effective amount. As used herein, the phrase "therapeutically effective amount" means a dose of VEGF antagonist that results in a detectable improvement in one or more symptoms or indicia of an angiogenic eye disorder, or a dose of VEGF antagonist that inhibits, prevents, lessens, or delays the progression of an angiogenic eye disorder. In the case of an anti-VEGF antibody or a VEGF receptor-based chimeric molecule such as VEGFR1R2-Fc $\Delta$ C1(a), a therapeutically effective amount can be from about 0.05 mg to about 5 mg,

Ex.1001, '338 patent, 6:48-58

(Paper 61, 7-12)

Ex.1001, '338 patent, claim 1



## "method for treating an angiogenic eye disorder in a patient"

### Challenged Claim 1 ('338 Patent):

## Intrinsic Evidence – The Specification

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

Petitioner: If limiting, "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22; Paper 61, 7) "Efficacy" is expressly defined "*[i]n the context of* methods for treating" covered by the Challenged Claims (e.g., claim 6)

week 48, by the end of week 56, etc. In the context of methods for treating angiogenic eye disorders such as AMD, CRVO, and DME, "efficacy" means that, from the initiation of treatment, the patient exhibits a loss of 15 or fewer letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual

Ex.1001, '338 patent, 7:24-28

6. The method of claim 1, wherein the angiogenic eye disorder is selected from the group consisting of: age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

Ex.1001, '338 patent, claim 1



DEMONSTRATIVE EXHIBIT – NOT EVIDENCE

(Paper 61, 2, 9-10)

## "method for treating an angiogenic eye disorder in a patient"

### Challenged Claim 1 ('338 Patent):

### Intrinsic Evidence – The Specification

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

Petitioner: If limiting, "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22; Paper 61, 7) Background "methods for treating" also make no mention of efficacy

Methods for treating eye disorders using VEGF antagonists are mentioned in, e.g., U.S. Pat. Nos. 7,303,746; 7,306, 799; 7,300,563; 7,303,748; and US 2007/0190058. Nonetheless, there remains a need in the art for new administration regimens for angiogenic eye disorders, especially those which allow for less frequent dosing while maintaining a high level of efficacy.

Ex.1001, '338 patent, 1:53-59 (Paper 61, 9-10, 13; Ex.1114, Albini, ¶ 23)

Only reference to a "high level of efficacy." Compare with Continental Circuits LLC v. Intel Corp., 915 F.3d 788, 798-99 (Fed. Cir. 2019) (absent clear disavowal, a preferred embodiment does not limit claim construction).

Ex.1001, '338 patent, claim 1



## "method for treating an angiogenic eye disorder in a patient"

### Challenged Claim 1 ('338 Patent):

## Intrinsic Evidence – The Prosecution History

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

Petitioner: If limiting, "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22; Paper 61, 7)

### Ex.1001, '338 patent, claim 1

PO emphasized treatment protocols and dosing frequency, <u>not</u> a "high level of efficacy"

Claims 1-20 were rejected under the judicially created doctrine of obviousness-type double patenting over claims 1-5 of U.S. Patent No. 7,303,746; claims 1-6 of U.S. Patent No. 7,303,747; claims 1-11 of U.S. Patent No. 7,306,799; and claims 1-15 of U.S. Patent No. 7,521,049.

In support of the rejection, it is argued that the claims of the cited patents claim methods of treating eye disorders. Although the rejection points out that the patents do not disclose schedules set within the current claims, it is argued that where the general conditions of a claim are disclosed within the prior art, it is not inventive to discover optimum or workable ranges by routine experimentation.

Due to all the above factors (1-5) there was a need in the art for <u>alternative treatment protocols</u> whereby the treatment would be carried out with less inconvenience and reduced safety risks to the patient. However, until the present invention once a month treatment remained the standard of care.

There are virtually an infinite number of different treatment protocols that could be tested. A drug could be administered more frequently, or less frequently, relative to the accepted standard of care. Further, different variations in timing between dosing events are possible. Due to the virtually infinite number of combinations, applicants do not believe that the claimed treatment protocol is *prima facie* obvious in view of the prior art standard of care which is administration of the drug once per month. **Ex.1017, '338 PH, 288-90 (Paper 1, 9-10; see also Paper 61, 9-10)** 



## "method for treating an angiogenic eye disorder in a patient"

### Challenged Claim 1 ('338 Patent):

### Intrinsic Evidence – The Prosecution History

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

Petitioner: If limiting, "administering a therapeutic to a patient, without a specific degree of efficacy required" (Paper 1, 20-22; Paper 61, 7) PO emphasized treatment protocols and dosing frequency, <u>not</u> a "high level of efficacy"

The Heier et al. paper shows results of a treatment protocol of the type claimed on over 2,400 patients. The studies summarized in the Heier *et al.* paper correspond to the clinical trials disclosed in Example 4 of the present application which involve the use of the VEGF receptor-based chimeric molecule known as aflibercept or "VEGF Trap."<sup>1</sup> The results clearly show that by administering the VEGF antagonist in accordance with a dosage regimen as claimed in independent claims 1 and 21, it is possible to treat angiogenic eye disorders such as AMD while administering doses on a less frequent basis than previously thought possible. This provides enormous benefits to patients, reduces health care cost, reduces the pain and suffering of the patient, as well as the inconvenience to the patient and their family, and as such provides a major step forward in the treatment of patients suffering from angiogenic eye disorders, which is worthy of patent protection.

#### Ex.1001, '338 patent, claim 1



**DEMONSTRATIVE EXHIBIT – NOT EVIDENCE** 

Ex.1017, '338 PH, 288-90 (Paper 1, 9-10)

## "method for treating an angiogenic eye disorder in a patient"

Requiring a "high level of efficacy" in the form of "visual acuit	ty
gains" excludes embodiments	

acuity chart. In certain embodiments, "efficacy" means a gain of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or more) letters on the ETDRS chart from the time of initiation of treatment.

Ex.1001, '338 patent, 7:29-32

- "[Courts] normally do not interpret claim terms in a way that excludes embodiments...." Oatey Co. v. IPS Corp., 514 F.3d 1271, 1276 (Fed. Cir. 2008)
- Absent clear disavowal, a preferred embodiment does not limit claim construction. *Continental Circuits LLC v. Intel Corp.*, 915 F.3d 788, 798-99 (Fed. Cir. 2019)

## Patent Owner's Proposal:

1. A method for treating an angiogenic eye disorder in a patient [that

achieves a high level of efficacy that is non-inferior to the standard of care,

for that particular angiogenic eye disorder, at the time of patent filing], said

Ex.1138, Do Dep. Ex.4 (Paper 61, 7-8)

"treat[ing] *requires* a high level of efficacy"

"visual acuity gains became the new standardof-care in treating wAMD"

(Paper 73, 3-4; Paper 40, 12-13; *see also* Paper 61, 13-14)



## "method for treating an angiogenic eye disorder in a patient"

Requiring a "high level of efficacy" in the form of "visual acuity gains" excludes embodiments					
Example 4			TABLE	1	
Phase III Clinical Trials of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGFT in Subjects with Neovascular Age-Related Macular Degeneration		Ranibizumab 0.5 mg monthly (RQ4)	VEGFT 0.5 mg monthly (0.5Q4)	VEGFT 2 mg monthly (2Q4)	VEGFT 2 mg every 8 weeks <sup>[a]</sup> (2Q8)
			of vision* <mark>(%</mark> at week 52 ve	patients losing <15 rsus baseline	
	Study 1 Study 2		96.3%** vement in visi	95.1%** 95.6%** on <sup>*</sup> (letters) at 52 value vs RQ4)***	95.1%** 95.6%**
	Study 1 Study 2	8.1 9.4	6.9 (NS) 9.7 (NS)	10.9 (p < 0.01) 7.6 (NS)	7.9 (NS) 8.9 (NS
	[e]Followin	a three initial monthly	doses		

**Dr. Brown (applying "high level of efficacy" construction):** Example 4 data does not "allow[] me to determine whether it's a method of treatment." Ex.1110, Brown Tr., 22:17-25:7 (Paper 61, 10)

### Patent Owner's Proposal:

1.	Α	method	for	treating	an	angiogenic	eye	disorder	in	а	patient	[that

achieves a high level of efficacy that is non-inferior to the standard of care

for that particular angiogenic eye disorder, at the time of patent filing], said

Ex.1138, Do Dep. Ex.4 (Paper 61, 7-8)

"treat[ing] *requires* a high level of efficacy"

"visual acuity gains became the new standardof-care in treating wAMD"

(Paper 73, 3-4; Paper 40, 12-13; *see also* Paper 61, 13-14)



## "initial dose," "secondary dose(s)" & "tertiary dose(s)"

### Challenged Claim 1 ('338 Patent):

#### Intrinsic Evidence – Lexicography

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose; and wherein each tertiary dose is administered at least 8 weeks after the immediately preceding dose;

Board: "[W]e find that the Specification expressly defines the terms 'initial dose,' 'secondary doses,' and 'tertiary doses.'" (Paper 21, 22-23) The terms "initial dose," "secondary doses," and "tertiary doses," refer to the temporal sequence of administration of the VEGF antagonist. Thus, the "initial dose" is the dose which is administered at the beginning of the treatment regimen (also referred to as the "baseline dose"); the "secondary doses" are the doses which are administered after the initial dose; and the "tertiary doses" are the doses which are administered after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of VEGF antagonist, but will generally differ from one another in terms of frequency of administration. In certain embodiments, however, the amount of VEGF antagonist contained in the initial, secondary and/or tertiary doses will vary from one another (e.g., adjusted up or down as appropriate) during the course of treatment.

Ex.1001, '338 patent, Claim 1

Ex.1001, '338 patent, 3:31-45



## "initial dose," "secondary dose(s)" & "tertiary dose(s)"

NEW ARGUMENT. PO (Sur-reply): "[I]f the Board chooses to construe these terms, PO's arguments regarding 'tertiary dose' apply with equal force to the 'initial dose' and 'secondary dose' terms." (Paper 73, 12; compare with Paper 40, 7 ("'initial dose' and

(Paper 73, 12; *compare with* Paper 40, 7 ("'initial dose' and 'secondary doses' <u>need not be construed</u>"))

**Board:** "[W]e do not find that the Specification requires the 'tertiary doses' to maintain any efficacy gain achieved after the initial and secondary doses, or that the term 'connotes a specific level of efficacy'" (Paper 21, 22-23)

## **Patent Owner's Proposal:**

method comprising sequentially administering to the patient a single initial dose
of a VEGF antagonist, followed by one or more secondary doses of the VEGF
antagonist, followed by one or more  doses, administered after the initial and
secondary doses, that maintain the efficacy gained after the initial and
secondary doses] of the VEGF antagonist;
wherein each secondary dose is administered 2 to 4 weeks after the
immediately preceding dose; and

wherein each [dose, administered after the initial and secondary doses,

that maintains the efficacy gained after the initial and secondary

doses] is administered at least 8 weeks after the immediately preceding

#### Ex.1138, Do Dep. Ex.4



## "initial dose," "secondary dose(s)" & "tertiary dose(s)"

PO does even not attempt to construe "tertiary dose(s)" separate from its arguments for "method for treating" (See Paper 40, 23-24 (incorporating by reference PO's arguments regarding the "method for treating" preamble requiring a high level of efficacy); Paper 73, 12-13 (same)) PO offers only extrinsic evidence which contradicts the intrinsic record on "tertiary dose(s)"	<ul> <li>method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more [doses, administered after the initial and secondary doses, that maintain the efficacy gained after the initial and secondary doses] of the VEGF antagonist;</li> <li>wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose; and</li> <li>wherein each [dose, administered after the initial and secondary doses] is administered after the initial and secondary doses] is administered after the initial and secondary doses] is administered after the initial and secondary doses]</li> </ul>
<b>Board:</b> "[PO] has not directed us to any portion of the Specification that teaches differently or adds any efficacy requirement to that definition [of 'tertiary doses']." (Paper 21, 23)	Ex.1138, Do Dep. Ex.4

**Patent Owner's Proposal:** 




# **Grounds 1-2 (Anticipation)**

## **Dixon & Adis**

LIFE SCIENCE LAW

## VIEW Q8 dosing regimen (with 3 loading doses) expressly disclosed



## **Grounds 3-5 (Anticipation)** REG (8-May-2008), NCT-795 (VIEW 1) & NCT-377 (VIEW 2)

"In the first year, the VIEW2 . . .

ctudy will avaluate the cafety and

## • VIEW Q8 dosing regimen (with 3 loading doses) expressly disclosed

(Paper 1, 31-36, 49-61)

	Study will evaluate the safety and	History of Changes for Study: NCT00509795	
	efficacy of VEGF Trap-Eye at	Vascular Endothelial Growth Pactor/VEGPTrap-Eyein/westigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) (VIEW1) Later veron underlide Desette 23, 2013 on Clined/Date sex	
REGENEROM Tay 5: 208 Bayes and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Methods and Study to evaluate efficacy and safety in tracing a leading catie of biology Instructional study to evaluate efficacy and safety in tracing a leading catie of biology Research and the second safety of the safety in tracing a leading catie of biology Research and the safety of the safety of the safety in tracing a leading catie of biology Research and the safety of the safety Research and the safety of the New York (String Freedy in Instance of the Safety of the New York (String Freedy in Instance of The Safety of the Safety of the safety of the safety of the Safety Research and the safety of the Safety Research and the Safety of the Safety Research and the Safety of the Safety	2.0 mg at an 8-week dosing interval, including one additional 2.0 mg dose at week four." (Ex.1013, REG (8-May-2008), 1-2)		Hang d'Darges fa July 167825227
Interded to stabilish non-interimity of UEO Trot-Eye with Learnest (Institutional), an antinangroupine signet approved for test in and AEO associate for about 00 parent of all server AEO/related vision lass. To social when abourd blood vasies in the off and about the continue groups with a stability of the about the social method. The contrast is a naple as a for an extension of the continue groups with a stability of the about the social method. The social was not of extension of the continue groups with a stability of the stability of the stability of the stability of the off extension of the continue groups and off cost the development and method of the spectrastic cost and blooks and improve stace). The stability of the stability of the cost of the stability of the stabilit		VEGF Trap-Eye: Investigati	changes for Study: NCT00537377 Ion of Efficacy and Safety in Wet AMD (VIEW 2), and headen 23 2014 of Dearline on
Change of the function in this confirmatory Plane 3 true is an generation missione for the compound interested to invasion advectaria data data and hand and plane advectaria. Which is and decays to "Associated", BLD, the function advectaria data data data data data data data da	"2.0 mg VEGF Trap-Eye administered every 8 weeks (including one additional 2.0 mg dose at week 4) during the first	segments the Protocol action of the star.     Source Control action of the Source Control action of the star.     Source Control Texas Source Control action of the Source Control action	must is spandy how for two shuly various an to be displayed. The Balo ky Salo Hourd only exe. In a stury for fur various. In country compared have: A plane table main includes the study various country's large avea. In the study of the study of the study of the study various country's large avea. In the study of the study of the study of the study various country's large avea. In the study of the study of the study of the study of the study various country's large avea. In the study of the study of the study of the study various country's large avea. In the study of the
Mydan U: Regenerus, IPRC 1991 Mydan U: Regenerus, IPRC 1991 Page 1 Page 1	year." (Ex.1014, NCT-795, 8; Ex.1015, NCT-377, 6) )8)	Ex.1015, N	Man Evene (1)5 Mylan v. Regeneren, IPRO201 Page 1

ory of Changes for Study: NCT0050979

NHR U.S. National Library of Medicine ClinicalTrials.gov archive

## **Ground 6 (Obviousness)**

## **Dixon (alone or combined with the '758 patent or Dix)**

## • VIEW Q8 dosing regimen (with 3 loading doses) expressly disclosed

	2.6.3 Phase III							
	A two part Phase III trial of VEGF Trap-Eye was initiated in							
	August of 2007. The first part, VIEW 1 (VEGF Trap:							
	Investigation of Efficacy and safety in Wet age-related macular							
	degeneration) 469 will enroll ~ 1200 patients with neovascu-							
	lar AMD in the US and Canada. This non-inferiority study							
Expert	will evaluate the safety and efficacy of intravitreal VEGF							
Opinion	Trap-Eye at doses of 0.5 and 2.0 mg administered at 4-week							
1. Introduction 2. Background	dosing intervals and 2.0 mg at an 8 week dosing interval							
3. Conclusion 4. Expert opition	(following three monthly doses), compared with 0.5 mg of							
	ranibizumab administered every 4 weeks. After the first year							
	milificantly improved the safe and effective treatment of nervascular AMD.							
	2.2 Introduction to compound							
	VEGF Trap-Eye is a novel anti-VEGF drug currently in							
	commercial development for the treatment of neovascular							
	AMD by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY,							
	USA) in the US and in collaboration with Bayer HealthCare							
	(Leverkusen, Germany) in global markets. Structurally,							
	VEGF Trap-Eye is a fusion protein of key binding domains							
	of human VEGFR-1 and -2 combined with a human IgG							
	Fc fragment (Figure 1). Functionally, VEGF Trap-Eye acts as							
-	dar introduction of plocodynamic theory (1071) which onlined a phonocentrizing							
informa .	2.3 Chemistry							
	VEGF Trap-Eye and aflibercept (the oncology product) have							
	the same molecular structure, but there are substantial dif-							
	Mylan v. Regeneron, IPR202100880 Page 1							

Ex.1006, Dixon, 1575-76



DEMONSTRATIVE EXHIBIT – NOT EVIDENCE

Claim 1 ('338): A method for treating an angiogenic eye disorder in a patient

... administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist

... wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose; and

... wherein each tertiary dose is administered at least 8 weeks after the immediately preceding dose...

FIG. 24A-24C. Nucleotide (SEQ ID NO:15) and deduced amino acid sequence (SEQ ID NO:16) of the modified Flt1 receptor termed VEGFR1R2-FcΔC1(a).

Ex.1010, '758 Patent, 10:15-17

(Paper 1, 36-37, 62-66)

51

## **Ground 6 (Obviousness)**

## **Dixon (alone or combined with the '758 patent or Dix)**

## VIEW Q8 dosing regimen (with 3 loading doses) expressly disclosed

#### 2.6.3 Phase III

Expert Opinion

informa


A two part Phase III trial of VEGF Trap-Eye was initiated in August of 2007. The first part, VIEW 1 (VEGF Trap: Investigation of Efficacy and safety in Wet age-related macular degeneration) 46 will enroll ~ 1200 patients with neovascular AMD in the US and Canada. This non-inferiority study will evaluate the safety and efficacy of intravitreal VEGF Trap-Eye at doses of 0.5 and 2.0 mg administered at 4-week dosing intervals and 2.0 mg at an 8 week dosing interval (following three monthly doses), compared with 0.5 mg of ranibizumab administered every 4 weeks. After the first year

Patients initially treated with 2.0 or 0.5 mg of VEGF Trap-Eye monthly achieved mean improvements of 9.0 (p < 0.0001) and 5.4 (p < 0.085) ETDRS letters with 29 and 19% gaining, respectively,  $\geq 15$  ETDRS letters at 52 weeks. During the p.r.n. dosing period, patients initially dosed on a 2.0 mg monthly schedule received an average of 1.6 more injections and those initially dosed on a 0.5 mg monthly schedule received an average of 2.5 injections. The median time to first Reasonable Expectation of Success: Dixon discloses positive Phase 2 ("CLEAR-IT-2") data which launched the VIEW trial. Ex.1006, Dixon, 1576 (after 52 weeks, Phase 2 patients required (on average) only 1.6 additional injections after four monthly loading doses) (Paper 1, 64-65; Paper 61, 32-33)

> Motivation to Combine with the '758 patent or Dix: Dixon expressly discloses dosing VEGF Trap-Eye (Paper 1, 63-64)


#### Ex.1006, Dixon, 1576





WWW.RMMSLEGAL.COM

## '069 Patent



Ex.1001, '069 Patent, 2:30-38



# Dixon

#### 2.2 Introduction to compound

VEGF Trap-Eye is a novel anti-VEGF drug currently in commercial development for the treatment of neovascular AMD by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA) in the US and in collaboration with Bayer HealthCare (Leverkusen, Germany) in global markets. Structurally, VEGF Trap-Eye is a fusion protein of key binding domains of human VEGFR-1 and -2 combined with a human IgG Fc fragment (Figure 1). Functionally, VEGF Trap-Eye acts as a receptor decoy with high affinity for all VEGF isoforms, binding more tightly than their native receptors. Unlike anti-VEGF drugs currently in use, VEGF Trap-Eye is designed to inhibit placental growth factors-1 and -2 in addition to all isoforms of VEGF-A.

#### 2.3 Chemistry

VEGF Trap-Eye and aflibercept (the oncology product) have the same molecular structure, but there are substantial differences between the preparation of the purified drug product and their formulations. Both aflibercept and VEGF Trap-Eye are manufactured in bioreactors from industry standard Chinese hamster ovary cells that overexpress the fusion protein. However, VEGF Trap-Eye undergoes further purification steps during manufacturing to minimize risk of irritation to the eye. VEGF Trap-Eye is also formulated with different buffers and at different concentrations (for buffers in common) suitable for the comfortable, non-irritating, direct injection into the eye. Dixon, Oliver, Olson & Ma

angiothat end in proceedynis, which are presumed us be similar recep-pathways that metabolics mitholics. At very high does not hat a differency has a terminal half-life of - 17 days in the doesn i uskin. The half-life of human introvirted doesn is unker arrendy Intravited primate doesn of rambinumb have a half-~3 days 181. At low blood levels, cleanate of free af cept is rupd as a result of binding to VEGP with picot

nti-VEGF drug currently in the treatment of acovacular citicali, Inc. (Taryrown, NY, zation with Bayer HealthCar foldal markets, Strastanallytool with a human IgG or did y building domaine miblied with a human IgG or did domaine and the strast of the strategy of intervenous affilia test of the strategy domaine miblied with a human IgG

man dependent toxicity when one patient developed hypertension and another proteinuria (se, i The safety, tolerability and biological activity of intravitrea 2 in VEGF Trap-Eye in treatment of norvascular AMD was eval

used in the two-pare Clinical Evolution of Ansi-singlegenesis in the Retrins [CL2ART-13] and (s); in The first part was a sequential cohort dose-scalation randy in which 21 pairents were monitored for single, change in forced thickness on OCT, bet corrected visual activity (BCVA) and lesion into on PAG of 6 weeks. No adverse synthesis co-calar certans were noted and visual activity remained studie or improved  $\ge 3$ lines in 59% of particus with a sense intense in BCVA of 4.66 lerrents at 6 weeks (ic. Pairins showed submanially determed from Hintense usin, a sense in a device immerging the sense of the sense

In the second part, 30 pairma received a single introvirual injection of either 50 of + mg of VSGT Tra-phy ran and were followed for 8 weeks. All paircas were evaluated for their rates of retrements, change in ECAV, foured takkness as well as dataget in total isolans size and area of CNV horizonts had ETDIS (EGAV) Transmers of Dabeies: Reninopathy Study) RCVA ranging from 2046 to 20233 with any anglographics ashyper of CNV at bashios. No serious advecvers no exolatr inflammation was identified during the study. A 8 weeks, he mean decrease in retain idializeoni in each, A 8 weeks, he mean decrease in retain idializeoni in retain differenti for the study of the second study of the study of the second study of the second study of the study of the second study of the secon

the low dose group was 63.7 µm compared to 175 µm for the high dose group. Of the first 24 parients to complete the study. 11 out of 12 patients in the 0.5 mg dose group required retransment in a molitan of 64 days, compared with 4 out of 12 in the 4 mg dose group who required retreatment in a median of 69 days (i). VEGF Timp-Dy has also undergone a small open-label

EAF imp-type has also undergone a small open-label yearly for the treatment of diabetic macular edema  $\mathbb{E}$  yed. The drug was administered as a single 4 mg virtual injection for paratients with longeanding diaand several previous treatments for DML: The single tion resulted in a median decrease of central macular mean measured by OCT of 79 µm. BCVA increased by the st 4 weeks and negressed to a 3 letter improvement

ctive VEGF-affibercept 9 letters at 4 weeks and regressed to a 3 letter impo notic mediated pathways at 6 weeks.


Mylan Exhibit 1006

Mylan v. Regeneron, IPR2021-00880 Page 3

Ex.1006, Dixon, 1575




# Dixon






# **Adis**





# **'758 PTE Application**

The name of the approved product is EYLEA<sup>™</sup>. The name of the active ingredient of EYLEA<sup>™</sup> is aflibercept, also known as VEGF trap, VEGF-trap, VEGF Trap-Eye and VEGF-TRAP<sub>R1R2</sub>. Aflibercept is a fusion protein consisting of (a) a vascular endothelial growth factor (VEGF) receptor component having immunoglobulin-like (Ig) domains consisting of an Ig domain 2 of a first VEGF receptor that is human Flt1 and an Ig domain 3 of a second VEGF receptor that is human Flk1; and (b) an Fc portion of human IgG1.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re U.S. Patent Number: 7,374,758


Ex.1024, '758 PTE, 2 (Paper 61, 22)



# **'758 PTE Application**

Holash further describes VEGFR1 and VEGFR2 on page 11393, in the second paragraph, as being "highly related transmembrane tyrosine kinases that use their ectodomains to bind VEGF." The disclosure of the Flt1 and Flk1 components in the approved product and the construction of the expression vector used in making the active ingredient in the approved product is discussed in the '758 patent in Example 20, column 29, lines 41-56. The amino acid sequence of both the Flt1 and Flk1 components of the approved product are disclosed in Figures 24A-24C. Flt1 Ig domain 2 spans amino acid residues 27 through 129 and Flk1 Ig domain 3 spans amino acid residues 130 through 231 of the fusion protein.

Aflibercept comprises the Fc domain of human IgG1 fused to the extracellular domains from the VEGF receptors. *See* section 11 of EYLEA<sup>™</sup> label, provided as Attachment B. A "multimerizing component" of the fusion protein of claim 1 can comprise an immunoglobulin domain, such as the Fc domain of IgG. *See* col. 5, lines 42-46 and col. 7, lines 25-30 of the '758 patent. Thus, aflibercept also includes a multimerizing component as defined in claim 1. The multimerizing component of the fusion protein, the Fc region of human IgG, is referenced throughout the '758 patent. The disclosure of the Fc multimerizing component in the actual product is discussed in Example 20, column 29, lines 41-56, and its amino acid sequence is disclosed in Figures 24A-24C, from amino acid residue 232 through 458.



ES PATENT AND TRADEMARK OFFICE

RECEIVED DEC 2/2 2011

eptides with etic Propertie

rd Vanconoul

Ex.1024, '758 PTE, 6-7 (Paper 1, 24-25)



<ol> <li>Identification of the Approved Product under 37 C.F.R. §1.740 (a)(1</li> </ol>	L) NTHE UNITED STATES PATENT AND TRADEMARK OFFICE
The name of the approved product is EYLEA <sup>™</sup> . The name of the active ingredient of EYLEA <sup>™</sup> is aflibercept, also known as VEGF trap, VEGF-trap, VEGF Eye and VEGF-TRAP <sub>R1R2</sub> . Aflibercept is a fusion protein consisting of (a) a vasc endothelial growth factor (VEGF) receptor component having immunoglobulin (Ig) domains consisting of an Ig domain 2 of a first VEGF receptor that is human and an Ig domain 3 of a second VEGF receptor that is human Flk1; and (b) an Fo portion of human IgG1.	A 2006 rgeneron Pharmaceuticals, Inc. Unit: OPLA I-like unit Legal Administration (via hand delivery) 2015 20
	appulant represents that it is the assignee of the entrie interest in and to the 950 parker by virtue of assignment of all rights of rivervals Nicholas J. Papadopoulos, Samuel Divis and George D. Yanoopoulos (Phapadopoulos et d.) to Regeneron Pharmacriticals, Inc., as recorded in Int U.S. Tatexta aff ar Andemark Office on August 13, 2001, Red 012077, France 0970 and on Pehranyr 19, 2002, Red 012659, France 0222 (a copy of each is attached in Attachment A. 81 FG1497 1128,81 %

Ex.1102, '959 PTE, 2 (Paper 61, 30, 36)



Aflibercept is also described in Holash et al. Proc. Natl. Acad. Sci USA, August 20, 2002, Vol. 99, No. 17, pp. 11393-11398 ("Holash," Attachment G) as VEGF-Trap<sub>R1R2</sub>, which has the Ig domain 2 of VEGF receptor 1 (VEGFR1; also known as Flt-1) fused to the Ig domain 3 of VEGF receptor 2 (VEGFR2; also known as Flk-1), which in turn is fused to the constant region (Fc) of human IgG1. See paragraph bridging pages 11393 and 11394 and Figure 1A. Moreover, Holash et al. demonstrate that aflibercept is a VEGF antagonist that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in various in vitro and in vivo assay systems.

IL THE ILLITE	D STATES PATENT AND TRADEMA	ARK OFFICE			
Acad. Sci.					
ash,"	7,070,959				
VEGF	852)				
VEUL	Polypeptides with cokinetic Properties	RECEIVED			
un 3 of		DEC 2, 2, 2011			
	, Davis and Yancopoulos	PATENT EXTENSION OPLA			
ı is fused					
ging	rmaceuticals, Inc.	Unit: OPLA			
00					
	ninistration (via hand delivery)				
o and	on Building)				
owth	XTENSION OF PATENT TERM UNDER 35 U.S.C. §156				
Applicant, Regeneron Pharmaceuticals, Inc., hereby submits this application for extension of the term of United States Letters Patent No. 7,070,959 (the ""959 patent") under 35 U.S.C. §156 and 37 C.F.R §1.740.					
Applicant represents that it is the assignee of the entire interest in and to the '959 patent by virtue of assignment of all rights of inventors Nicholas J. Papadopoulos, Samuel Davis and George D. Yancopoulos (Papadopoulos et al.) to Regeneron Pharmaceuticals, Inc., as recorded in the U.S. Patent and Trademark Office on August 13, 2001, Reel 012077, Frame 0978 and on February 19, 2002, Reel 012639, Frame					

@1 EC+1457

05/09/2912 CKHLOK 00800010 188650 7070959

1128.88 DA

Ex.1102, '959 PTE, 5 (Paper 61, 30, 36)

0222 (a copy of each is attached in Attachment A).



	-
As noted in Section 11 of the EYLEA™ label (Attachment B),	IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by	10/000 852)
recombinant DNA technology. Holash (Attachment G) also describe	sthe
method of producing aflibercept (VEGF-Trap <sub>R1R2</sub> ) as expressing a recombinant DNA construct in Chinese hamster ovary cells (See	iy 4, 7006 Regeberon Pharmaceuticals, Inc. Unit: OPLA
"Engineering VEGF-Traps" in the Materials and Methods section on	atom Legal Administration (via hand delivery) W 7055 19 Street (Madison Bailding) a. VA 22314
page 11393-11394).	ICATION FOR EXTENSION OF PATENT TERM UNDER 35 U.S.C. §156
	nicani, Regeneron Pharmaceuticals, Inc., hereby submits this application on of the term of Uniced States Letters Planet No. 7,070,959 (the "959 patent") under 51 USC, 515 64n 37 C.7 RR 1,2740. Applicant represents that it is the assignce of the entire interest in and to the
	959 pattern by virtue of assignment of all rights of inventors Nichalas J. Papadopoulos, Samuel Davis and George D. Nacospoulos (Papadopoulos et al.) to Regeneron Pharmacestacias, inc., as recorded in the VS. Pattern and Trademark Office on August 13, 2001, Feel 01 2077, Frame 1997 and on February 19, 2002, Red 10 2059, Frame 0222 (a copy of each is attached in Antachment A). By Seynet States and State States
	61 (fc167 1128.09 30
	Mylan Exhibit 11 Mylan v. Regeneron, IPR2021-002 Pan

Ex.1102, '959 PTE, 5 (Paper 61, 30, 36)




(2) Explanation Regarding Claim 11 Relative to Aflibercept	
As explained below, a method for manufacturing aflibercept, the active ingredient of the approved product, is covered by at least claim 11.	IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Claim 11 reads as follows:	(Application No. 10/009,852) For: Modified Chimeric Polypeptides with RECEIVED Improved Pharmacokinetic Properties DEC 2.32 2011 Inventors: Papadopoulos, Davis and Yancopoulos PATENT EXTENSION USB 06
11. A method of producing a fusion polypeptide, comprising growing cells of the host-vector system of claim 8, under	Assigner: Regeneron Pharmaceuticals, Inc. Unit: OPLA Offices of Patent Legal Administration (via hand delivery) Room MDW 7D55 600 Duany Street (Madison Building) Alexandria, VA 22314
conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.	APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 U.S.C. §156 Dear Sir, Applicant, Regeneron Pharmaceuticals, Inc., hereby submits this application for extension of the term of United States Letters Patent No. 7.070,959 (the "559
Claim 11 depends from claim 8, which reads as follows:	patent?) under 35 U.S.C §156 and 37 CF.R §1.740. Applicant represents that it is the assignee of the entire interest in and to the 959 patent by virtue of assignment of all rights of inventors Nicholas J. Papadopoulos, Samuel Davis and George D. Yancopoulos (Papadopoulos de d) to Regeneron Pharmaceutical, Inc., as recorded in the U.S. Patent and Trademath Office on August 13, 2001, Red (01207), Frame 05978 and on Pebrary 13, 2002, Red (012639, Frame 10222 (a copy of each is statched in Attachment A
8. A host-vector system for the production of a fusion	BURNOUL LINKA ANNA ANNA ANNA ANNA ANNA ANNA ANNA
polypeptide comprising an expression vector encoding a fusion protein capable of binding VEGF, wherein the fusion protein	Mytan E-tribit 1102 Mytan v. Regeneron, IPR2021-00880 Page 1
consists of immunoglobulin-like (Ig) domain 2 of VEGF receptor human Flt1, Ig domain 3 of VEGF receptor human Flk1, and a multimerizing component, in a suitable isolated host cell.	Ex.1102, '959 PTE, 5-6 (Paper 61, 30, 36)



Claim 11 describes a method of producing the fusion polypeptide encoded by the expression vector in the host-vector system of claim 8 comprising growing cells of the host-vector system under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide. As described above, aflibercept is a fusion polypeptide encoded by the expression vector in the host-vector system of claim 8. Therefore, growing cells of the host-vector system under conditions permitting production of the encoded fusion polypeptide according to claim 11 will produce aflibercept. Thus, claim 11 is directed to a method of manufacturing aflibercept, the active ingredient of the approved product.

Example 20 at col. 29, lines 13-29 of the '959 patent describes the construction of a nucleic acid (VEGFR1R2-Fc $\Delta$ C1(a))encoding a fusion protein having the three components of aflibercept. The nucleic acid and amino acid sequence of VEGFR1R2-Fc $\Delta$ C1(a) is provided in Figures 24A-C. See col. 9, lines 65-67. Thus, aflibercept is a fusion

protein encoded by a nucleic acid sequence of SEQ ID NO: 15. The nucleotides encoding the various components of aflibercept are further described in Figures 24A-24C, whereby the Flt1 Ig domain 2 is encoded by nucleotide residues 80 through 389, the Flk1 Ig domain 3 is encoded by nucleotide residues 390 through 693 and the Fc component is encoded by nucleotide residues 694 through 1377.



Ex.1102, '959 PTE, 6-7 (Paper 61, 30, 36)



#### **CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a true and correct copy of the foregoing Petitioner's Corrected Demonstratives for Oral Argument was served on August 9, 2022, via electronic mail by agreement of the parties, to the following counsel for

record of Patent Owners:

Deborah E. Fishman (Reg. No. 48,621) David A. Caine (Reg. No. 52,683) Arnold & Porter Kaye Scholer LLP 3000 El Camino Real Five Palo Alto Square, Suite 500 Palo Alto, California 94306-3807 Telephone: 650.319.4519 Telephone: 650.319.4573 Deborah.Fishman@arnoldporter.com David.Caine@arnoldporter.com

Daniel Reisner Matthew M. Wilk Arnold & Porter Kaye Scholer LLP 250 West 55th Street New York, New York 10019-9710 Telephone: 212.836.8000 Fax: 212.836.8689 Daniel.Reisner@arnoldporter.com Matthew.Wilk@arnoldporter.com Alice S. Ho (Lim. Rec. No. L1162) Victoria Reines Jeremy Cobb Arnold & Porter Kaye Scholer LLP 601 Massachusetts Ave., N.W. Washington D.C. 20001 Tel: 202.942.5000 Fax: 202.942.5999 Alice.Ho@arnoldporter.com Victoria.Reines@arnoldporter.com

/Paul J. Molino/ Paul J. Molino (Reg. No. 45,350)